drugset / Trial / NCT01119066
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food and Drug Administration (FDA) has not yet approved it.
Timeline
- Start
- 2010-05-03
- Primary completion
- 2021-03-30
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 0.8 mg/kg | — |
| Subject | Clofarabine | Other / unclassified | 20 mg/m2 | — |
| Subject | Clofarabine | Other / unclassified | 30 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 60 mg/kg | — |
| Subject | Fludarabine | Small molecule | 25 mg/m2 | — |
| Subject | Melphalan | Small molecule | 70 mg/m2 | — |
| Subject | Thiotepa | Other / unclassified | 5 mg/kg | — |
| Subject | Thiotepa | Other / unclassified | 10 mg/kg | — |